Neurocrine Biosciences, Inc. (NBIX): a potential bargain?

Buy — a solid, growing, profitable drugmaker got hit for an unexciting-but-not-bad earnings report, not for any real bad news.

🔥 HOT Fundamentals89/100

Fell 10% in 1 trading day(s) — now $166.80

Why NBIX dropped

The drop coincides exactly with Neurocrine's Q2 2026 earnings release (reported July 30, stock fell 10% July 31): the selloff appears tied to a quarterly update that was viewed as mixed rather than clearly better than expected, even though demand for key products remained solid, likely because investors wanted a guidance increase or bigger revenue beat and the company instead largely reaffirmed its existing outlook. Actual results were solid: in Q2 2026 Neurocrine reported revenue of US$959.0 million and net income of US$144.4 million, with earnings per share rising year over year, while six-month revenue reached US$1.77 billion and net income US$342.3 million.

Fwd P/E 13.7Op margin 22.2%Rev growth 39.5%Debt/equity 12.5%Analyst upside 26.6%

How this scored 89/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 20.9%

✅ Generates cash Free cash flow $638M

✅ Not drowning in debt Debt/equity 12.5% (limit 200%)

✅ Can pay its bills Current ratio 1.9 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 23/25

Operating margin 22.2% 8/9

Net profit margin 20.9% 8/8

Return on equity 22.1% 7/8

Growth Is it getting bigger, or dying? 25/25

Revenue growth 39.5% 9/9

Earnings growth 31.1% 8/8

Expected profit change 78.1% 8/8

Value Is it cheap right now? 19/25

Forward P/E 13.7 8/10

PEG ratio 0.5 8/8

Analyst target upside 26.6% 3/7

Balance sheet Will it survive? 22/25

Debt / equity 12.5% 10/10

Current ratio 1.9 5/8

Free cash flow $638M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for NBIX — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-03. Research only — not financial advice.